Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke

Link to the Inserm press review  (in French)

J.-L. Mas, G. Derumeaux, B. Guillon, E. Massardier, H. Hosseini, L. Mechtouff, C. Arquizan, Y. Béjot, F. Vuillier, O. Detante, C. Guidoux, S. Canaple, C. Vaduva, N. Dequatre‑Ponchelle, I. Sibon, P. Garnier, A. Ferrier, S. Timsit, E. Robinet‑Borgomano, D. Sablot, J.-C. Lacour, M. Zuber, P. Favrole, J.-F. Pinel, M. Apoil, P. Reiner, C. Lefebvre, P. Guérin, C. Piot, R. Rossi, J.-L. Dubois‑Randé, J.-C. Eicher, N. Meneveau, J.-R. Lusson, B. Bertrand, J.-M. Schleich, F. Godart, J.-B. Thambo, L. Leborgne, P. Michel, L. Pierard, G. Turc, M. Barthelet, A. Charles‑Nelson, C. Weimar, T. Moulin, J.-M. Juliard, and G. Chatellier, for the CLOSE Investigators*



Trials of patent foramen ovale (PFO) closure to prevent recurrent stroke have been inconclusive. We investigated whether patients with cryptogenic stroke and echocardiographic features representing risk of stroke would benefit from PFO closure or anticoagulation, as compared
with antiplatelet therapy.


In a multicenter, randomized, open-label trial, we assigned, in a 1:1:1 ratio, patients 16 to 60 years of age who had had a recent stroke attributed to PFO, with an associated atrial septal aneurysm or large interatrial shunt, to transcatheter PFO closure plus long-term antiplatelet
therapy (PFO closure group), antiplatelet therapy alone (antiplatelet-only group), or oral anticoagulation (anticoagulation group) (randomization group 1). Patients with contraindications to anticoagulants or to PFO closure were randomly assigned to the alternative noncontraindicated treatment or to antiplatelet therapy (randomization groups 2 and 3). The primary outcome was occurrence of stroke. The comparison of PFO closure plus antiplatelet therapy with antiplatelet therapy alone was performed with combined data from randomization groups 1 and 2, and the comparison of oral anticoagulation with antiplatelet therapy alone was performed with combined data from randomization groups 1 and 3.


A total of 663 patients underwent randomization and were followed for a mean (±SD) of 5.3±2.0 years. In the analysis of randomization groups 1 and 2, no stroke occurred among the 23 patients in the PFO closure group, whereas stroke occurred in 14 of the 235 patients in the antiplatelet- only group (hazard ratio, 0.03; 95% confidence interval, 0 to 0.26; P<0.001). Procedural complications from PFO closure occurred in 14 patients (5.9%). The rate of atrial fibrillation was higher in the PFO closure group than in the antiplatelet-only group (4.6% vs. 0.9%, P = 0.02). The number of serious adverse events did not differ significantly between the treatment groups (P = 0.56). In the analysis of randomization groups 1 and 3, stroke occurred in 3 of 187 patients assigned to oral anticoagulants and in 7 of 174 patients assigned to antiplatelet therapy alone.


Among patients who had had a recent cryptogenic stroke attributed to PFO with an associated atrial septal aneurysm or large interatrial shunt, the rate of stroke recurrence was lower among those assigned to PFO closure combined with antiplatelet therapy than among those assigned to antiplatelet therapy alone. PFO closure was associated with an increased risk of atrial fibrillation. (Funded by the French Ministry of Health; CLOSE number, NCT00562289.)

This part of the website could either be in French or English, depending on the sources of the actualities.

Autres Publications

 28 mai 2019
Kremen1-induced cell death is regulated by homo- and heterodimerization
 20 mai 2019
Impaired attentional modulation of sensorimotor control and cortical excitability in schizophrenia
 06 mai 2019
Routing Hippocampal Information Flow through Parvalbumin Interneuron Plasticity in Area CA2
 30 avril 2019
Individual recovery profiles of manual dexterity, and relation to corticospinal lesion load and excitability after stroke —a longitudinal pilot study
 11 avril 2019
Neuronal activity in vivo enhances functional myelin repair
 10 avril 2019
Somatostatin Serves a Modulatory Role in the Mouse Olfactory Bulb: Neuroanatomical and Behavioral Evidence
 13 février 2019
A new painkiller nanomedicine to bypass the blood-brain barrier and the use of morphine
 11 février 2019
Live Tracking of Inter-organ Communication by Endogenous Exosomes In Vivo
 06 février 2019
Mitochondria, Metabolism, and Redox Mechanisms in Psychiatric Disorders
 09 janvier 2019
In vivo Optogenetic Approach to Study Neuron-Oligodendroglia Interactions in Mouse Pups
 21 décembre 2018
Predictive Modulation of Corticospinal Excitability and Implicit Encoding of Movement Probability in Schizophrenia
 07 novembre 2018
Manual Dexterity and Aging: A Pilot Study Disentangling Sensorimotor From Cognitive Decline
 05 novembre 2018
Burnout in medical students before residency: A systematic review and meta-analysis
 03 octobre 2018
Tobacco Smoking and Psychotic-Like Experiences in a General Population Sample
 14 juin 2018
The GABAergic Gudden's dorsal tegmental nucleus: A new relay for serotonergic regulation of sleep-wake behavior in the mouse
 07 juin 2018
a2- and b2-Adrenoreceptor-Mediated Efficacy of the Atypical Antidepressant Agomelatine Combined With Gabapentin to Suppress Allodynia in Neuropathic Rats With Ligated Infraorbital or Sciatic Nerve
 18 mai 2018
Memory circuits: CA2
 07 mai 2018
Cortical developmental death: selected to survive or fated to die
 05 avril 2018
Plasma amyloid levels within the Alzheimer’s process and correlations with central biomarkers
 02 mars 2018
Longitudinal Analyses of Blood Transcriptome During Conversion to Psychosis.